Literature DB >> 14726712

Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes.

Shannon L McDonald1, Howard D Edington, John M Kirkwood, Dorothea Becker.   

Abstract

Microarray profiling is a powerful approach to establish gene expression patterns for different histopathological stages of a malignancy, and at the same time, to identify individual genes that may have important functions in the early and/or advanced stages of a neoplasm. To identify genes that hitherto have not been shown to be expressed or play a role in advanced-stage melanomas, we conducted microarray analyses with RNAs from primary melanoma and melanoma-positive lymph node specimens. Using RT-PCR, quantitative, real-time RT-PCR, and fluorochrome oligonucleotide-based optical imaging, we established the level and pattern of expression of five of the identified known genes [Suppression of Tumorigenicity 13 (ST13), Cystatin 8 (CST-8), Dyskeratosis Congentia 1 (DKC1), Neuroendocrine Secretory Protein 55 (NESP55), Niemann-Pick Disease, type C2 (NP-C2)], and a gene with unknown function (16.7 kD Hypothetical Protein) in benign and atypical nevocytic lesions, advanced-stage melanomas, and melanoma-positive lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726712     DOI: 10.4161/cbt.3.1.662

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  9 in total

1.  Correlation of dyskerin expression with active proliferation independent of telomerase.

Authors:  Faizan Alawi; Ping Lin; Barry Ziober; Reena Patel
Journal:  Head Neck       Date:  2010-12-08       Impact factor: 3.147

2.  Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma.

Authors:  Andrey S Dobroff; Hua Wang; Vladislava O Melnikova; Gabriel J Villares; Maya Zigler; Li Huang; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

3.  A meta-analysis of transcriptome datasets characterizes malignant transformation from melanocytes and nevi to melanoma.

Authors:  Daniel Ortega-Bernal; Claudia H González-De La Rosa; Elena Arechaga-Ocampo; Miguel Angel Alvarez-Avitia; Nora Sobrevilla Moreno; Claudia Rangel-Escareño
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

Review 4.  Non-canonical roles of canonical telomere binding proteins in cancers.

Authors:  Semih Can Akincilar; Claire Hian Tzer Chan; Qin Feng Ng; Kerem Fidan; Vinay Tergaonkar
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

5.  Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma.

Authors:  Yuchun Luo; Steven Robinson; Junichi Fujita; Lisa Siconolfi; Jay Magidson; Carl K Edwards; Karl Wassmann; Kathleen Storm; David A Norris; Danute Bankaitis-Davis; William A Robinson; Mayumi Fujita
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

6.  A functional connection between dyskerin and energy metabolism.

Authors:  Alberto Angrisani; Nunzia Matrone; Valentina Belli; Rosario Vicidomini; Nunzia Di Maio; Mimmo Turano; Filippo Scialò; Paolo Antonio Netti; Antonio Porcellini; Maria Furia
Journal:  Redox Biol       Date:  2017-11-06       Impact factor: 11.799

7.  Changes on the Caco-2 secretome through differentiation analyzed by 2-D differential in-gel electrophoresis (DIGE).

Authors:  Andrés García-Lorenzo; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; María Páez de la Cadena; Vicenta S Martínez-Zorzano
Journal:  Int J Mol Sci       Date:  2012-11-07       Impact factor: 5.923

8.  Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis.

Authors:  Bei Liu; Jinglei Zhang; Chen Huang; Hui Liu
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

9.  The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer.

Authors:  Khloud A Elsharawy; Omar J Mohammed; Mohammed A Aleskandarany; Ayman Hyder; Hekmat L El-Gammal; Mohamed I Abou-Dobara; Andrew R Green; Leslie W Dalton; Emad A Rakha
Journal:  Br J Cancer       Date:  2020-09-01       Impact factor: 9.075

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.